Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 3, 2004, Pages

  Stein, Steven ^a   DeMichele, Angie ^a   Domchek, Susan ^a   Fox, Kevin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Combination therapy; Fluorescence in situ hybridization; Immunohistochemistry

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESPONSE; FATIGUE; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA;

EID: 1642339735     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.s.005     Document Type: Article

References (28)

1. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Gusterson BA, Gelber RD, Price KN, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10:1049-1056.
4. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
5. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6:2356-2362.
6. Baselga J, Seidman AD, Rosen PP, et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology (Hunting) 1997; 11:43-48.
7. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18:3651-3664.
8. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-4289.
9. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
11. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herception monotherapy in metastatic breast cancer. Oncology 2001; 61(suppl 2):37-42.
12. Leyland-Jones B, Arnold A, Gelmon K, et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol 2001; 12(suppl)1:S43-S47.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
14. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221.
15. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000; 27(6 suppl 11): 21-25.
16. Hirsch FR, Helfrich B, Franklin WA, et al. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer 2002; 3(supp 1):12-16.
17. Miller KD, Sisk J, Ansari R, et al. Gemcitabine, praclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001; 15:38-40.
18. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003; 30:22-26.
19. Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drugs sensitivity in human breast and ovarian cancer cell. Oncogne 1997; 15:537-547.
20. Bunn PA, Jr, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and flourescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001; 7:3239-3250.
21. Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002; 16:1576-1578.
22. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002; 62:2-8.
23. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736.
24. Possinger K, Kaufman M, Coleman R, et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drug 1999; 10:155-162.
25. Gerson R, Derrano-O A, Villalobos A, et al. Gemcotabine response in advance breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Oncol 2000; 19:145a (Abstract #572).
26. Valerio M, Cicero G, Armata M, et al. Gemcitabine (G) in pretreated breas cancer. Proc Am Soc Clin Oncol 2001; 20:51b (Absract #1953).
27. Brodowicz T, Kostler WJ, Moslinger R. Single agent gemcitabine as second-and third-line treatment in metastatic breast cancer. Breast 2000; 9:338-342.
28. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60:303-307.